title: Haemoglobin targets: we were wrong, time to move on.
authors.affiliation: Cochrane Renal Group and Centre for Kidney Research and NHMRC Centre for Clinical Research Excellence in Renal Medicine, School of Public Health, University of Sydney, Sydney, New South Wales, Australia. strippoli@negrisud.it
authors.forename: Giovanni F M
authors.initials: GF
authors.lastname: Strippoli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Tognoni
authors.forename: Sankar D
authors.initials: SD
authors.lastname: Navaneethan
authors.forename: Antonio
authors.initials: A
authors.lastname: Nicolucci
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Craig
mesh_terms: D000740:Anemia / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006454:Hemoglobins / Q000187:drug effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012306:Risk
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin